RWE Oncology Market, By Component (Datasets, Integrated Datasets, and Consulting Services), By Data Source Type, By Therapeutic Area, By Application, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4713
|
Published Date
February 2026
|
Pages
380
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
RWE Oncology Market size was valued at US$ 790.10 Million in 2024, expanding at a CAGR of 14.90% from 2025 to 2032.
Real-World Evidence (RWE) in oncology refers to the collection and analysis of healthcare data from real-world settings—such as electronic health records, patient registries, and insurance claims—to complement and enhance insights generated from clinical trials. RWE supports evaluations of treatment effectiveness, post-market safety monitoring, and personalized cancer care decision-making. Market growth is driven by the rising global burden of cancer and the increasing adoption of value-based healthcare models. According to the National Cancer Institute (NCI), approximately 1.9 million new cancer cases were diagnosed in the United States in 2024, underscoring the growing need for real-world data to improve therapeutic outcomes. Advances in data analytics, artificial intelligence integration, and expanding regulatory acceptance are further accelerating the use of RWE in oncology, enabling faster drug development, improved clinical insights, and optimized patient management worldwide.
RWE Oncology Market- Market Dynamics
Rising Adoption of Real-World Data to Improve Oncology Treatment Outcomes
The rising global cancer burden and the growing need for personalized, evidence-based oncology care are key drivers of demand for real-world evidence (RWE) solutions. According to the World Health Organization (WHO), cancer remains one of the leading causes of death worldwide, accounting for nearly 10 million deaths in 2024. This has intensified the use of real-world data from electronic health records, cancer registries, and claims databases to complement clinical trial findings, enhance treatment effectiveness, and strengthen post-market safety monitoring.
Regulatory agencies, including the U.S. Food and Drug Administration (FDA), are increasingly accepting RWE to support drug approvals and label expansions, accelerating market adoption. Advances in artificial intelligence and machine learning are enabling deeper insights from complex oncology datasets, supporting the advancement of precision medicine. In parallel, healthcare payers and providers are prioritizing value-based care models, leveraging RWE to optimize treatment pathways, improve outcomes, and control costs. Growing investments in health IT infrastructure across both developed and emerging economies are further expanding market growth opportunities worldwide.
RWE Oncology Market- Segmentation Analysis:
The Global RWE Oncology Market is segmented on the basis of Component, Data Source Type, Therapeutic Area, Application, End User, and Region.
Based on component, the oncology real-world evidence (RWE) market comprises data sources, analytics software, and services. Data sources form the foundation of the market, encompassing electronic health records (EHRs), cancer registries, insurance claims and billing data, patient-reported outcomes, and genomic databases, all of which provide longitudinal and population-level insights essential for oncology research. Analytics software plays a central role by applying artificial intelligence and machine learning algorithms to interpret complex oncology datasets, enabling assessment of treatment effectiveness, safety signals, and outcome prediction across diverse patient populations. Services, including consulting, data integration, and data management, support healthcare organizations, pharmaceutical companies, and research institutions in effectively deploying RWE solutions. Government initiatives continue to expand data availability globally; for example, public health authorities report that more than 85% of hospitals in developed healthcare systems now use certified electronic health record platforms, significantly strengthening the data infrastructure required for oncology RWE generation and analysis.
Based on application, the market spans drug development and clinical trials, treatment optimization, regulatory and payer decision support, and market access and reimbursement. In drug development, RWE is increasingly used to complement clinical trial data, supporting accelerated approvals, post-marketing studies, and label expansions. Treatment optimization leverages real-world patient data to personalize therapy selection, improve outcomes, and reduce adverse events in routine oncology care. Regulatory and payer decision support relies on RWE for post-market safety monitoring, health technology assessment, and evidence-based coverage decisions. Market access and reimbursement applications benefit from RWE by demonstrating real-world treatment value, clinical effectiveness, and cost efficiency, which are critical for payer negotiations and formulary inclusion. Globally, regulatory agencies such as the U.S. FDA, European Medicines Agency, and national health authorities increasingly recognize RWE as a formal decision-making tool, with government health systems reporting expanded use of real-world data in oncology policy, reimbursement frameworks, and population-level cancer outcome monitoring.
RWE Oncology Market- Geographical Insights
The global real-world evidence (RWE) oncology market demonstrates notable regional variation, influenced by differences in healthcare infrastructure, data availability, and regulatory frameworks. North America leads the market, supported by a high cancer burden and advanced data ecosystems. According to the National Cancer Institute (NCI), more than 1.9 million new cancer cases were projected in the United States in 2024, driving strong demand for real-world data to improve treatment outcomes. Adoption is further accelerated by the U.S. FDA’s Real-World Evidence Program, which promotes the use of RWE in regulatory decision-making.
Europe follows, with robust oncology research capabilities and coordinated data initiatives. The European Cancer Information System reports nearly 4 million new cancer cases annually, supporting widespread RWE adoption across major oncology hubs and research networks. The Asia-Pacific region is expected to experience the fastest growth, fueled by rising cancer incidence and expanding digital health infrastructure. China’s National Cancer Center estimated approximately 4.8 million new cancer diagnoses in 2023, prompting increased investment in healthcare data platforms and digital oncology solutions. Emerging regions, including Latin America and the Middle East, are also gaining traction as growing cancer prevalence and government-led efforts to improve healthcare data collection and analytics create new opportunities for RWE adoption and market expansion.
U.S. RWE Oncology Market- Country Insights
The United States leads the global real-world evidence (RWE) oncology market, driven by its advanced healthcare ecosystem, extensive oncology research capabilities, and strong regulatory support for real-world data integration. According to the National Cancer Institute (NCI), approximately 1.9 million new cancer cases are projected in the U.S. in 2024, creating urgent demand for enhanced treatment evaluation and outcome assessment through RWE. The U.S. Food and Drug Administration’s Real-World Evidence Program supports faster regulatory approvals and improved post-market surveillance, further accelerating market growth. Key industry players, including Flatiron Health, IQVIA, and Tempus Labs, are leveraging large-scale clinical datasets, AI-driven analytics, and partnerships with leading cancer centers to advance real-world oncology insights. Additionally, the United States benefits from a robust health IT infrastructure, high healthcare spending—exceeding USD 4.3 trillion in 2023, according to the Centers for Medicare & Medicaid Services (CMS)—and continuous innovation in precision oncology, positioning the country as the global hub for RWE applications in oncology.
RWE Oncology Market- Competitive Landscape:
The growing emphasis on data-driven oncology care and the expanding use of real-world evidence (RWE) are intensifying competition among key market players. Leading companies such as IQVIA, ICON plc, Syneos Health, Parexel, Covance, and Flatiron Health are strengthening their market positions by leveraging advanced data analytics platforms, AI-enabled insights, and comprehensive oncology data registries. Common competitive strategies include strategic acquisitions to enhance data and analytics capabilities, partnerships with pharmaceutical and biotechnology companies to deliver tailored oncology solutions, and geographic expansion to access diverse patient populations and real-world datasets. Significant investments in cloud-based data management platforms and real-time evidence generation tools are enabling faster clinical insights, streamlined drug development, and more efficient regulatory submissions. In parallel, companies are prioritizing compliance with evolving data privacy regulations while offering customized RWE solutions to meet the complex needs of oncology research, further strengthening their global competitive positions.
Recent Developments:
- May 2025: Datavant completed its acquisition of Aetion, a specialist in real-world evidence analytics, combining data connectivity and advanced RWE capabilities into a unified platform. The expanded ecosystem—encompassing over 300 data partners across EHRs, claims, registries, and other sources—aims to enable life sciences and healthcare organizations to generate faster, scalable, and actionable evidence across the drug development lifecycle.
- April 2025: Atropos Health partnered with Ontada to integrate Ontada’s community oncology real-world data into the Atropos Evidence™ Network. This collaboration is designed to enhance RWE use cases for clinicians, researchers, and healthcare leaders, supporting improved cancer care protocols, advancing precision medicine, and accelerating the development of new oncology therapies through high-quality real-world evidence.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RWE ONCOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- IQVIA
- ICON plc
- Syneos Health
- Parexel International
- Covance (Labcorp)
- PPD, Inc.
- PRA Health Sciences (now part of ICON)
- Charles River Laboratories
- Medidata Solutions (Dassault Systèmes)
- Clarivate
- Flatiron Health (owned by Roche)
- Cerner Corporation (now part of Oracle)
- Cota Healthcare
- Evidera (PAREXEL)
- RealEndeavors
- Truven Health Analytics (IBM Watson Health)
- Informa Pharma Intelligence
- McKesson Corporation
- Symphony Health (ICON)
- Others
GLOBAL RWE ONCOLOGY MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032
- Datasets
- EMR/HER
- Claims
- Pharmacy
- Cancer Registries
- Integrated Datasets
- Consulting Services
GLOBAL RWE ONCOLOGY MARKET, BY DATA SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032
- Clinical Data
- Claims Data
- Oncology Registries
- Pharmacy Data
GLOBAL RWE ONCOLOGY MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Hematologic Malignancies
- Others
GLOBAL RWE ONCOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Drug Development & Approvals
- Market Access & Reimbursement
- Post-Market Surveillance
- Medical Device Approvals
- Others
GLOBAL RWE ONCOLOGY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Pharmaceutical, Biotechnology & Medical Device Companies
- Healthcare Providers
- Healthcare Payers
- Others
GLOBAL RWE ONCOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. RWE Oncology Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. RWE Oncology Market Snippet by Component
2.1.2. RWE Oncology Market Snippet by Data Source Type
2.1.3. RWE Oncology Market Snippet by Therapeutic Area
2.1.4. RWE Oncology Market Snippet by Application
2.1.5. RWE Oncology Market Snippet by End User
2.1.6. RWE Oncology Market Snippet by Country
2.1.7. RWE Oncology Market Snippet by Region
2.2. Competitive Insights
3. RWE Oncology Key Market Trends
3.1. RWE Oncology Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. RWE Oncology Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. RWE Oncology Market Opportunities
3.4. RWE Oncology Market Future Trends
4. RWE Oncology Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. RWE Oncology Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. RWE Oncology Market Landscape
6.1. RWE Oncology Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. RWE Oncology Market – By Component
7.1. Overview
7.1.1. Segment Share Analysis, By Component, 2024 & 2032 (%)
7.1.2. Datasets
7.1.2.1. EMR/HER
7.1.2.2. Claims
7.1.2.3. Pharmacy
7.1.2.4. Cancer Registries
7.1.3. Integrated Datasets
7.1.4. Consulting Services
8. RWE Oncology Market – By Data Source Type
8.1. Overview
8.1.1. Segment Share Analysis, By Data Source Type, 2024 & 2032 (%)
8.1.2. Clinical Data
8.1.3. Claims Data
8.1.4. Oncology Registries
8.1.5. Pharmacy Data
9. RWE Oncology Market – By Therapeutic Area
9.1. Overview
9.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
9.1.2. Breast Cancer
9.1.3. Lung Cancer
9.1.4. Prostate Cancer
9.1.5. Hematologic Malignancies
9.1.6. Others
10. RWE Oncology Market – By Application
10.1. Overview
10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
10.1.2. Drug Development & Approvals
10.1.3. Market Access & Reimbursement
10.1.4. Post-Market Surveillance
10.1.5. Medical Device Approvals
10.1.6. Others
11. RWE Oncology Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Pharmaceutical, Biotechnology & Medical Device Companies
11.1.3. Healthcare Providers
11.1.4. Healthcare Payers
11.1.5. Others
12. RWE Oncology Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. RWE Oncology Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. RWE Oncology Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. RWE Oncology Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. RWE Oncology Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. RWE Oncology Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- RWE Oncology Industry
13.1. Competitive Benchmarking
13.1.1. Competitive Dashboard
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. IQVIA
13.2.2. ICON plc
13.2.3. Syneos Health
13.2.4. Parexel International
13.2.5. Covance (Labcorp)
13.2.6. PPD, Inc.
13.2.7. PRA Health Sciences (now part of ICON)
13.2.8. Charles River Laboratories
13.2.9. Medidata Solutions (Dassault Systèmes)
13.2.10. Clarivate
13.2.11. Flatiron Health (owned by Roche)
13.2.12. Cerner Corporation (now part of Oracle)
13.2.13. Cota Healthcare
13.2.14. Evidera (PAREXEL)
13.2.15. RealEndeavors
13.2.16. Truven Health Analytics (IBM Watson Health)
13.2.17. Informa Pharma Intelligence
13.2.18. McKesson Corporation
13.2.19. Symphony Health (ICON)
13.2.20. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RWE ONCOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- IQVIA
- ICON plc
- Syneos Health
- Parexel International
- Covance (Labcorp)
- PPD, Inc.
- PRA Health Sciences (now part of ICON)
- Charles River Laboratories
- Medidata Solutions (Dassault Systèmes)
- Clarivate
- Flatiron Health (owned by Roche)
- Cerner Corporation (now part of Oracle)
- Cota Healthcare
- Evidera (PAREXEL)
- RealEndeavors
- Truven Health Analytics (IBM Watson Health)
- Informa Pharma Intelligence
- McKesson Corporation
- Symphony Health (ICON)
- Others
GLOBAL RWE ONCOLOGY MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032
- Datasets
- EMR/HER
- Claims
- Pharmacy
- Cancer Registries
- Integrated Datasets
- Consulting Services
GLOBAL RWE ONCOLOGY MARKET, BY DATA SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032
- Clinical Data
- Claims Data
- Oncology Registries
- Pharmacy Data
GLOBAL RWE ONCOLOGY MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Hematologic Malignancies
- Others
GLOBAL RWE ONCOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032
- Drug Development & Approvals
- Market Access & Reimbursement
- Post-Market Surveillance
- Medical Device Approvals
- Others
GLOBAL RWE ONCOLOGY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Pharmaceutical, Biotechnology & Medical Device Companies
- Healthcare Providers
- Healthcare Payers
- Others
GLOBAL RWE ONCOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
